MetaCap

Akari Therapeutics (AKTX) vs Pasithea Therapeutics (KTTA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Pasithea Therapeutics (KTTA) has outperformed Akari Therapeutics (AKTX) over the past year, gaining 63.9% versus a loss of 60.1%. Over five years, KTTA leads with a -99.4% price change compared with -99.5% for AKTX. Pasithea Therapeutics is the larger company by market cap ($17.6 million vs $16.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AKTX-60.11%KTTA+63.94%
+428%+160%-107%
Nov 21, 20251 yearNov 20, 2026
AKTX-99.41%KTTA-98.99%
+78%-15%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AKTX versus KTTA key metrics
MetricAKTXKTTA
Share price$7.18$0.4787
Market cap$16.70M$17.59M
1-day change+7.00%-0.48%
YTD return-37.89%-62.89%
1-year return-60.11%+63.94%
5-year return-99.47%-99.40%
EPS (TTM)$0.00$-1.38
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-17.30M$-20.43M
52-week high$29.32$2.06
52-week low$3.02$0.32
Distance from 52-week high-75.51%-76.76%
Analyst consensusnonenone
Avg. price target upside+255.15%+526.70%
Average volume58.54K705.64K
Shares outstanding2.33M36.75M
Employees55
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • KTTA has outperformed AKTX by 124.0 percentage points over the past year.

About Akari Therapeutics

AKTX stock →

Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

About Pasithea Therapeutics

KTTA stock →

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

AKTX vs KTTA FAQ

Which is bigger, Akari Therapeutics or Pasithea Therapeutics?

Pasithea Therapeutics (KTTA) is larger, with a market capitalization of $17.59M compared with $16.70M for Akari Therapeutics (AKTX).

Which stock has performed better over the past year, AKTX or KTTA?

KTTA returned +63.94% over the past 12 months, compared with -60.11% for AKTX (price return, excluding dividends). Past performance does not predict future results.

Are Akari Therapeutics and Pasithea Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons